IL-17 induces inflammation-Associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood

Journal of Investigative Dermatology

Volumn 134, Issue 12, 2014, Pages 2990-2993

  Wang, Claire Q F ^a   Suárez Fariñas, Mayte ^a   Nograles, Kristine E ^a   Mimoso, Claudia A ^a   Shrom, David ^b   Dow, Ernst R ^b   Heffernan, Michael P ^b   Hoffman, Robert W ^b   Krueger, James G ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BETA1 INTEGRIN; CD18 ANTIGEN; CD31 ANTIGEN; CD99 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 6; IXEKIZUMAB; PROTEIN CDC42; STAT3 PROTEIN; THROMBOSPONDIN 1; TRANSCRIPTOME; CHEMOKINE RECEPTOR; CYTOKINE; MONOCLONAL ANTIBODY;

ALOX5 GENE; ALOX5AP GENE; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL ACTIVITY; GENE EXPRESSION; GENE PRODUCT; HUMAN; INFLAMMATION; LETTER; MACROPHAGE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; PSORIASIS; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; UPREGULATION; CELL CULTURE; DOSE RESPONSE; DRUG EFFECTS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-17; MONOCYTES; PSORIASIS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84909948434     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2014.268     Document Type: Letter

References (29)

1. Abuabara K, Lee H, Kimball AB (2011) The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 165:1066-73
2. Ahlehoff O, Skov L, Gislason G et al. (2013) Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 273: 197-204
3. Back M (2009) Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm Des 15:3116-32
4. Boring L, Gosling J, Cleary M et al. (1998) Decreased lesion formation in CCR2 mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394:894-7
5. Davidovici BB, Sattar N, Prinz JC et al. (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 130:1785-96
6. Di Gregoli K, Johnson JL (2012) Role of colonystimulating factors in atherosclerosis. Curr Opin Lipidol 23:412-21
7. Ding HS, Yang J, Ding JW et al. (2011) Interleukin- 17 contributes to cardiovascular diseases. Mol Biol Rep 39:7473-8
8. Dixon WG, Watson KD, Lunt M et al. (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56:2905-12
9. Holm T, Damas JK, Holven K et al. (2003) CXCchemokines in coronary artery disease: possible pathogenic role of interactions between oxidized low-density lipoprotein, platelets and peripheral blood mononuclear cells. J Thromb Haemost 1:257-62
10. Jacobsson LT, Turesson C, Gulfe A et al. (2005) Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 32: 1213-8
11. Kerekes G, Soltesz P, Der H et al. (2009) Effects of biologics on vascular function and atherosclerosis associated with rheumatoid arthritis. Ann N Y Acad Sci 1173:814-21
12. Krueger JG, Fretzin S, Suárez-Fariñas M et al. (2012) IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 130:e149
13. Madhur MS, Funt SA, Li L et al. (2011) Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol 31:1565-72
14. Mastroianni A, Minutilli E, Mussi A et al. (2005) Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 153:531-6
15. Mehta NN, Azfar RS, Shin DB et al. (2010) Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 31:1000-6
16. Mizutani H, Ohmoto Y, Mizutani T et al. (1997) Role of increased production of monocytes TNF-Alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments. J Dermatol Sci 14:145-53
17. Moura R, Tjwa M, Vandervoort P et al. (2008) Thrombospondin-1 deficiency accelerates atherosclerotic plaque maturation in ApoE mice. Circ Res 103:1181-9
18. Okubo Y, Koga M (1998) Peripheral blood monocytes in psoriatic patients overproduce cytokines. J Dermatol Sci 17:223-32
19. Papp KA, Griffiths CE, Gordon K et al. (2013) Longterm safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 168:844-54
20. Pietrzak A, Bartosinska J, Chodorowska G (2013) Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol 52:153-62
21. Rousselle A, Qadri F, Leukel L et al. (2013) CXCL5 limits macrophage foam cell formation in atherosclerosis. J Clin Invest 123:1343-7
22. Shahrara S, Pickens SR, Dorfleutner A et al. (2009) IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 182:3884-91
23. Smith E, Prasad KM, Butcher M et al. (2010) Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice. Circulation 121:1746-55
24. Strober B, Teller C, Yamauchi P et al. (2008) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 159:322-30
25. Suárez-Fariñas M, Li K, Fuentes-Duculan J et al. (2012) Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol 132:2552-64
26. Tzellos T, Kyrgidis A, Zouboulis CC (2013) Reevaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-Analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 27:622-7
27. Wen J, Zhang JQ, Huang W et al. (2012) SDF-1alpha and CXCR4 as therapeutic targets in cardiovascular disease. Am J Cardiovasc Dis 2:20-8
28. Woollard KJ, Geissmann F (2010) Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 7:77-86
29. Yost J, Gudjonsson JE (2009) The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbidities. F1000 Med Rep 1